Sometimes, good news just isn't enough. Shares of Alumis Inc. (ALMS) tumbled more than 11% on Monday. The weird part? This happened right after the company shared some genuinely encouraging results from late-stage trials for its lead drug candidate. So what gives? It looks like a classic case of investors deciding to lock in some profits after a truly spectacular run—the stock is up a staggering 239% over the past 12 months. Even promising science can take a backseat to simple math when gains get that big.

The Data Is Actually Pretty Good

Let's talk about the science, because it's the reason the stock ran up in the first place. Over the weekend, Alumis released detailed results from two Phase 3 trials for envudeucitinib, a treatment for moderate-to-severe plaque psoriasis. The numbers tell a compelling story.

Roughly three out of four patients saw their scalp psoriasis become clear or almost clear by Week 24. Even better, patients started reporting significant improvements in their quality of life and itch relief as early as Week 4—well before their skin showed maximum clearance. That's a big deal for a chronic condition; feeling better quickly matters.

The gold-standard measures for skin clearance, called PASI 90 and PASI 100, also showed strong results. By Week 24, between 62% and 68% of patients on the drug achieved PASI 90 (meaning 90% skin clearance), and between 39% and 41% hit PASI 100 (complete clearance). These figures handily beat the placebo groups and build on positive topline data the company released back in January. The takeaway: the drug appears to work, and it starts working fast.

The Path to the FDA

With this data in hand, Alumis is moving forward. The company plans to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of this year. That's the next major milestone, turning promising trial results into a potential marketable product.

What the Charts Are Saying

So, with good news and a regulatory plan, why the sell-off? This is where the charts and some market psychology come in. After a rocket-ship ride like the one Alumis has been on, it's natural for some investors to cash out. The technical indicators reflect this pause.

The stock is currently trading well below its 20-day and 50-day simple moving averages (by about 20% and 21%, respectively), which suggests short-term bearish pressure. However, it's still trading about 14% above its 100-day moving average, hinting that the longer-term uptrend might still be intact. The Relative Strength Index (RSI) sits at a neutral 45.35, suggesting the stock isn't extremely overbought or oversold. But the Moving Average Convergence Divergence (MACD) indicator is in negative territory and below its signal line, which is typically read as a bearish signal.

In plain English: the short-term momentum has cooled off significantly, but it's not necessarily a full-blown reversal yet. Traders are watching key levels, with resistance seen around $26.50 and support down near $18.00.

What the Analysts Think

Despite Monday's drop, Wall Street analysts are still broadly positive. The consensus rating is a Buy, with an average price target of $33.42, which implies a decent chunk of upside from current levels. But a look at recent actions shows there's a range of opinions on just how much upside:

• Oppenheimer is the most bullish, raising its price target to $55.00 on March 30 with an Outperform rating.
• Chardan Capital maintained a Buy rating and a $38.00 target on the same date.
• HC Wainwright & Co. also kept a Buy rating but lowered its target to $25.00, also on March 30.

That's a pretty wide spread—from $25 to $55—which itself tells you there's some debate about the right value here following the big run-up.

At the end of the day, Alumis shares closed Monday's session down 11.69% at $21.90. It's a reminder that in biotech investing, stellar past performance and solid clinical data can still run into the reality of traders taking profits. The story now shifts to the FDA submission and whether the longer-term trend can reassert itself once this wave of selling passes.